Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study found that a new deoxycholic acid derivative may offer a similar prostatoprotective effect to finasteride with lower toxicity in rat models.

This study found that the "After Minoxidil" spray improved hair styling and decreased greasiness after using topical minoxidil, which may enhance compliance and effectiveness.

A woman experienced excessive hair growth after using a hair loss treatment with minoxidil.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

In this study, researchers found that exosome-like nanoparticles isolated from Polygoni Multiflori Radix can promote hair growth in mice by modulating androgen signaling and gene expression, outperforming Minoxidil in testosterone-induced conditions.

This study found that minoxidil solubilized in gelatin-containing microemulsions resulted in over 5% of the drug remaining in porcine skin, significantly more than the reference gel.

In this randomized study, BAY 1158061, a prolactin receptor antibody, was found to be safe, well-tolerated, and exhibited low immunogenicity in healthy postmenopausal women, but had no effect on serum prolactin levels compared to placebo.

This study found that minoxidil in Espumil Foam Base remains stable for at least 90 days when stored at room temperature and protected from light.

This study found that finasteride microemulsions significantly increased skin permeability in vitro, highlighting the potential for enhanced delivery of this drug through the skin.

This study found that a new propylene glycol-free 5% minoxidil lotion demonstrated good clinical efficacy and very good cosmetic acceptability and tolerability after six months of use in patients with androgenetic alopecia, showing results comparable to traditional formulations containing propylene glycol.

This study developed a spring-driven microneedle booster that improved early and cumulative delivery of minoxidil, accelerating hair regrowth compared to traditional roller methods in an androgenetic alopecia model.

Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.

A new compound was made that might help treat diseases related to male hormones.

This study found that multiple ion channel modulators, used here at clinical concentrations, increased intracellular calcium release in prostate and breast cancer cell lines.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

In this retrospective study, among transfeminine patients aged 19-81 receiving gender-affirming estrogen therapy, 100% achieved testosterone suppression without anti-androgens when serum estradiol exceeded 100pg/mL, predominantly using injectable estrogen.

This phase 1 study reported that after administering supratherapeutic doses of cortexolone 17α‐propionate, a topical antiandrogen intended for hair loss treatment, there was no effect on the QTc interval, indicating no measurable cardiac safety concerns in the concentration range tested.

A new compound that could treat various androgen-related conditions was created and analyzed.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This study found that combining oral minoxidil, oral dutasteride, and dutasteride mesotherapy was the most effective treatment for androgenetic alopecia, with improved outcomes at 12 months and a favorable safety profile, compared to other treatment combinations.

This study synthesized nonsteroidal ligands as second-generation androgen receptor agonists and identified three compounds with significant anabolic activity and moderate to minimal androgenic activity in vivo.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

In this study, among postmenopausal women with female androgenetic alopecia, the combination of Pygeum africanum and Serenoa repens extracts at higher doses plus MSM significantly increased total hair growth and hair resistance compared to a lower dose formulation after 16 weeks.